Clinical Trial Update: Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating prophylactic house dust mite allergen immunotherapy to prevent childhood asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases
• Asthma

Drugs mentioned

• House dust mite allergen immunotherapy (house dust mite allergen immunotherapy)

Snippet

Sponsor: Boston Children's Hospital | Conditions: Asthma, Allergy | Phase 2 | Status: WITHDRAWN